vs
AMICUS THERAPEUTICS, INC.（FOLD）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是AMICUS THERAPEUTICS, INC.的1.1倍（$207.3M vs $185.2M），AMICUS THERAPEUTICS, INC.净利率更高（0.9% vs -62.0%，领先62.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 23.7%），AMICUS THERAPEUTICS, INC.自由现金流更多（$16.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 29.5%）
Amicus Therapeutics是总部位于美国宾夕法尼亚州费城的生物制药上市企业，2007年在纳斯达克挂牌上市，股票代码为FOLD。上市前，公司曾获得Radius Ventures、迦南合伙人、恩颐投资等多家风险投资机构的资金支持，专注于生物医药领域的研发与商业化布局。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FOLD vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.2M | $207.3M |
| 净利润 | $1.7M | $-128.6M |
| 毛利率 | 85.7% | — |
| 营业利润率 | 8.6% | -54.7% |
| 净利率 | 0.9% | -62.0% |
| 营收同比 | 23.7% | 25.9% |
| 净利润同比 | -88.5% | 3.5% |
| 每股收益（稀释后） | $0.00 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $185.2M | $207.3M | ||
| Q3 25 | $169.1M | $159.9M | ||
| Q2 25 | $154.7M | $166.5M | ||
| Q1 25 | $125.2M | $139.3M | ||
| Q4 24 | $149.7M | $164.6M | ||
| Q3 24 | $141.5M | $139.5M | ||
| Q2 24 | $126.7M | $147.0M | ||
| Q1 24 | $110.4M | $108.8M |
| Q4 25 | $1.7M | $-128.6M | ||
| Q3 25 | $17.3M | $-180.4M | ||
| Q2 25 | $-24.4M | $-115.0M | ||
| Q1 25 | $-21.7M | $-151.1M | ||
| Q4 24 | $14.7M | $-133.2M | ||
| Q3 24 | $-6.7M | $-133.5M | ||
| Q2 24 | $-15.7M | $-131.6M | ||
| Q1 24 | $-48.4M | $-170.7M |
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | — | ||
| Q2 25 | 90.2% | — | ||
| Q1 25 | 90.7% | — | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | — | ||
| Q2 24 | 91.1% | — | ||
| Q1 24 | 87.7% | — |
| Q4 25 | 8.6% | -54.7% | ||
| Q3 25 | 20.3% | -106.9% | ||
| Q2 25 | -6.1% | -64.8% | ||
| Q1 25 | -6.3% | -102.6% | ||
| Q4 24 | 10.7% | -74.3% | ||
| Q3 24 | 15.3% | -94.6% | ||
| Q2 24 | 11.8% | -79.1% | ||
| Q1 24 | -25.1% | -151.9% |
| Q4 25 | 0.9% | -62.0% | ||
| Q3 25 | 10.2% | -112.8% | ||
| Q2 25 | -15.8% | -69.0% | ||
| Q1 25 | -17.3% | -108.5% | ||
| Q4 24 | 9.8% | -80.9% | ||
| Q3 24 | -4.8% | -95.7% | ||
| Q2 24 | -12.4% | -89.5% | ||
| Q1 24 | -43.9% | -156.8% |
| Q4 25 | $0.00 | $-1.28 | ||
| Q3 25 | $0.06 | $-1.81 | ||
| Q2 25 | $-0.08 | $-1.17 | ||
| Q1 25 | $-0.07 | $-1.57 | ||
| Q4 24 | $0.05 | $-1.34 | ||
| Q3 24 | $-0.02 | $-1.40 | ||
| Q2 24 | $-0.05 | $-1.52 | ||
| Q1 24 | $-0.16 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $293.5M | $421.0M |
| 总债务越低越好 | $392.7M | — |
| 股东权益账面价值 | $274.2M | $-80.0M |
| 总资产 | $949.9M | $1.5B |
| 负债/权益比越低杠杆越低 | 1.43× | — |
8季度趋势，按日历期对齐
| Q4 25 | $293.5M | $421.0M | ||
| Q3 25 | $263.8M | $202.5M | ||
| Q2 25 | $231.0M | $176.3M | ||
| Q1 25 | $250.6M | $127.1M | ||
| Q4 24 | $249.9M | $174.0M | ||
| Q3 24 | $249.8M | $150.6M | ||
| Q2 24 | $260.1M | $480.7M | ||
| Q1 24 | $239.6M | $112.3M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $-80.0M | ||
| Q3 25 | $230.4M | $9.2M | ||
| Q2 25 | $204.3M | $151.3M | ||
| Q1 25 | $193.6M | $144.2M | ||
| Q4 24 | $194.0M | $255.0M | ||
| Q3 24 | $178.8M | $346.8M | ||
| Q2 24 | $132.5M | $432.4M | ||
| Q1 24 | $130.7M | $140.3M |
| Q4 25 | $949.9M | $1.5B | ||
| Q3 25 | $868.8M | $1.2B | ||
| Q2 25 | $815.3M | $1.3B | ||
| Q1 25 | $789.8M | $1.3B | ||
| Q4 24 | $785.0M | $1.5B | ||
| Q3 24 | $786.6M | $1.5B | ||
| Q2 24 | $749.5M | $1.6B | ||
| Q1 24 | $721.8M | $1.3B |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $16.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 8.6% | -48.6% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 9.62× | — |
| 过去12个月自由现金流最近4个季度 | $29.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $16.3M | $-99.8M | ||
| Q3 25 | $35.7M | $-91.4M | ||
| Q2 25 | $-26.5M | $-108.3M | ||
| Q1 25 | $7.8M | $-166.5M | ||
| Q4 24 | $-3.9M | $-79.3M | ||
| Q3 24 | $-23.0M | $-67.0M | ||
| Q2 24 | $22.7M | $-77.0M | ||
| Q1 24 | $-29.7M | $-190.7M |
| Q4 25 | $16.0M | $-100.8M | ||
| Q3 25 | $35.3M | $-92.7M | ||
| Q2 25 | $-28.9M | $-110.7M | ||
| Q1 25 | $7.5M | $-167.8M | ||
| Q4 24 | $-4.2M | $-79.5M | ||
| Q3 24 | $-23.3M | $-68.6M | ||
| Q2 24 | $21.6M | $-79.0M | ||
| Q1 24 | $-31.5M | $-193.9M |
| Q4 25 | 8.6% | -48.6% | ||
| Q3 25 | 20.9% | -58.0% | ||
| Q2 25 | -18.7% | -66.5% | ||
| Q1 25 | 6.0% | -120.5% | ||
| Q4 24 | -2.8% | -48.3% | ||
| Q3 24 | -16.5% | -49.2% | ||
| Q2 24 | 17.0% | -53.7% | ||
| Q1 24 | -28.5% | -178.2% |
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.2% | 0.8% | ||
| Q2 25 | 1.6% | 1.5% | ||
| Q1 25 | 0.2% | 1.0% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.3% | 1.2% | ||
| Q2 24 | 0.9% | 1.4% | ||
| Q1 24 | 1.6% | 3.0% |
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
